<DOC>
	<DOCNO>NCT02939599</DOCNO>
	<brief_summary>This long-term open-label safety extension Phase 2a study inhale QCC374 adult patient PAH . This study provide patient complete QCC374X2201 study option continue receive QCC374 . The study monitor long-term safety , tolerability efficacy QCC374 patient PAH .</brief_summary>
	<brief_title>Long-term Extension Study Safety Pharmacokinetics QCC374 PAH Patients</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<criteria>Written informed consent must obtain assessment perform . Subject enrol QCC374X2201 study complete per protocol Subjects start receive prostacyclin ( epoprostenol ) , prostacyclin analog ( i.e . trepostinil , iloprost , beraprost ) prostacyclin receptor agonist ( i.e . selexipag ) since last study drug intake QCC374X2201 study . Females pregnant , plan become pregnant study , breastfeed Any known factor disease may interfere treatment compliance study conduct ( i.e . drug alcohol dependence ) Subjects withdrew consent study QCC374X2201</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Pulmonary hypertension ( PH ) ,</keyword>
	<keyword>Increase blood pressure pulmonary artery</keyword>
	<keyword>Increased blood pressure pulmonary vein</keyword>
	<keyword>Increased blood pressure lung vasculature</keyword>
	<keyword>Shortness breath</keyword>
	<keyword>Dizziness</keyword>
	<keyword>Fainting</keyword>
	<keyword>Leg swell</keyword>
	<keyword>Cough</keyword>
	<keyword>Angina pector</keyword>
</DOC>